We have added Cougar Biotechnology to our evaluated company list. With a focus on oncology, Cougar’s business strategy consists of in-licensing clinical stage drugs and moving them through development toward commercialization. The Los Angeles based company was established in 2003 and began trading publicly under the symbol CGRB in February 2007.

Cougar’s clinical stage pipeline includes three drugs: Abiraterone Acetate (CB7630), CB3304 (Noscapine) and CB1089 (Seocalcitol). The most advanced drug, Abiraterone, is being studied in a phase III trial for prostate cancer and a phase I/II trial in breast cancer will begin later this year. CB3304 is being developed for non-Hodgkin’s lymphoma and multiple myeloma (phase I/II) and CB1089 for prostate cancer (initiation of a phase I trial is on hold).

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.